No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Decernotinib is a type of immune disorder drug used to treat a variety of conditions, including psoriasis, rheumatoid arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, meaning it works by blocking the activity of certain enzymes that are involved in the body's inflammatory response. Decernotinib is taken orally and is available in both tablet and capsule form. It is generally well-tolerated, with the most common side effects being nausea, headache, and diarrhea.
Decernotinib is a relatively new drug, having only been approved by the US Food and Drug Administration (FDA) in 2019. It is currently being studied in clinical trials for the treatment of other immune-related conditions, such as atopic dermatitis and Crohn's disease.
The decernotinib market is highly competitive, with several companies offering their own versions of the drug. These include AbbVie, Amgen, Eli Lilly, and Pfizer. Other companies, such as Novartis and Merck, are also researching and developing their own versions of the drug. Show Less Read more
